HROW Stock Analysis: Buy, Sell, or Hold?

HROW - Harrow, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$40.95
-1.11 (-2.64%) â–ŧ
5d: +2.3%
30d: -2.22%
90d: +24.24%
WAIT
LOW Confidence
Protect Your HROW Gains
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026 0d
Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 11, 2026 at $39.70 · last confirmed Aug 18, 2026

Strength: 4.3/10

Get Alerted When HROW Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
â„šī¸ NEUTRAL: HROW is fairly priced but lacks strong directional signals. At -5.9% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$95.40
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$59.23
30.9% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.9x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: HROW is currently trading at $40.95, which is considered slightly low relative to its 30-day fair value range of $38.47 to $42.93. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.0) compared to its historical average (17.9). Remarkably, the market is currently pricing in an annual earnings decline of 5.9% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, HROW is in a uptrend. Immediate support is located at $37.70, while resistance sits at $43.00.

Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $67.50 (+64.8%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY LOW
Historical Trading Range $38.47 - $42.93
Company Quality Score 48/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 79.5%

Protect Your Profits

Holding HROW? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (53/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 64.8% below Wall St target ($67.50)
  • WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $38.47 - $42.93
Current vs Trading Range SLIGHTLY LOW

Support & Resistance Levels

Support Level $37.70
Resistance Level $43.00
Current Trend Uptrend
Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 14.96
Wall Street Target $67.50 (+64.8%)
Revenue Growth (YoY) 10.9%
Earnings Growth (YoY) -10.3%
Profit Margin -13.5%
Valuation Discount vs History -5.9% cheaper
PE vs Historical 15.0 vs 17.9 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -5.9% (market-implied from PE analysis)
1-Year Target $38.53 (-6%)
2-Year Target $36.26 (-12%)
3-Year Target $34.12 (-17%)
3-Yr Target (if PE normalizes) (PE: 15→18) $40.82 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.1, Growth: 877.4%) $185.37 (+353%)
Base: (SPY PE: 15.0, Growth: 877.4%) $138.21 (+238%)
Bear: (PE: 12.7, Growth: 877.4%) $117.48 (+187%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.0 to 17.9
Stabilization Target: $48.99 (+19.6%)
PE Expansion Potential: +19.6%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 23, 2026 7:50 AM ET
Data refreshes hourly during market hours. Next update: 8:50 AM
đŸ”Ĩ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for HROW.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences Iâ€Ļ
STRONG BUY
25 analysts
$212 67 BUY
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$107 56 HOLD
ZTS
Zoetis Inc
BUY
20 analysts
$101 43 HOLD
UTHR
United Therapeutics Corpâ€Ļ
STRONG BUY
15 analysts
$653 48 HOLD
LQDA
Liquidia Technologies Inc
STRONG BUY
10 analysts
$108 55 HOLD

Advanced HROW Option Strategies

Professional options setups generated by AI based on today's HROW price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for HROW

HROW Technical Chart HROW Price Prediction HROW Earnings Date HROW Investment Advisor HROW Fair Price Analyzer HROW Options Advisor HROW Options Chain HROW Options Analysis HROW Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals